Skip to main content
Top
Published in: European Radiology 3/2010

01-03-2010 | Contrast Media

Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents

Authors: Hanno Hoppe, Sara Spagnuolo, Johannes M. Froehlich, Helga Nievergelt, Hans-Peter Dinkel, Silvia Gretener, Harriet C. Thoeny

Published in: European Radiology | Issue 3/2010

Login to get access

Abstract

Purpose

The purpose was to retrospectively review the data of 27 patients with renal insufficiency who underwent conventional angiography with gadolinium-based contrast agents (GDBCA) as alternative contrast agents and assess the occurrence of nephrogenic systemic fibrosis (NSF) together with associated potential risk factors.

Methods

This HIPAA-compliant study had institutional review board approval, and informed consent was waived. Statistical analysis was performed for all available laboratory and clinical data, including dermatology reports. Type and amount of the GDBCA used were recorded for angiography and additional MRI studies, if applicable. Serum creatinine levels (SCr) pre- and post-angiography were recorded, and estimated glomerular filtration rates (eGFR) were calculated.

Results

Ten female and 17 male patients who underwent angiography with GDBCA were included. The mean amount of GDBCA administered was 44 ± 15.5 ml (range 15–60 ml) or 0.24 + 0.12 mmol/kg (range 0.1–0.53 mmol/kg). At the time of angiography all patients had renal insufficiency (eGFR <60 ml/min/1.73 m2). Mean eGFR pre-angiography was 26 ml/min/1.73 m2 and 33 ml/min/1.73 m2 post-angiography. The mean follow-up period covers 28 months, range 1–84 months. Additional MRI studies with GDBCA administration were performed in 15 patients. One patient with typical skin lesions had developed biopsy-confirmed NSF.

Conclusion

Conventional arterial angiography with GDBCA may play a role in the development of NSF in patients with renal insufficiency. Alternative contrast agents, such as CO2 angiography or rather the use of low doses of iodinated contrast agents, should be considered in these patients.
Literature
1.
go back to reference Spinosa DJ, Angle JF, Hagspiel KD, Kern JA, Hartwell GD, Matsumoto AH (2000) Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11:35–43CrossRefPubMed Spinosa DJ, Angle JF, Hagspiel KD, Kern JA, Hartwell GD, Matsumoto AH (2000) Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11:35–43CrossRefPubMed
2.
go back to reference Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, McGraw JK, Ayers C (1999) Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. Radiology 210:663–672PubMed Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, McGraw JK, Ayers C (1999) Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. Radiology 210:663–672PubMed
3.
go back to reference Thomsen HS, Almen T, Morcos SK (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605PubMed Thomsen HS, Almen T, Morcos SK (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605PubMed
4.
go back to reference Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, Cage D, Bissonette EA et al (2001) Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol 176:1305–1311PubMed Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, Cage D, Bissonette EA et al (2001) Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol 176:1305–1311PubMed
5.
go back to reference Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765CrossRefPubMed Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765CrossRefPubMed
6.
go back to reference Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18:614–617CrossRefPubMed Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18:614–617CrossRefPubMed
7.
go back to reference Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209–212PubMed Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209–212PubMed
8.
go back to reference Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108CrossRefPubMed Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108CrossRefPubMed
9.
go back to reference High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–26CrossRefPubMed High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–26CrossRefPubMed
10.
go back to reference Thomsen HS, Marckmann P, Logager VB (2007) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7:130–137CrossRefPubMed Thomsen HS, Marckmann P, Logager VB (2007) Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7:130–137CrossRefPubMed
11.
go back to reference Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313–318CrossRefPubMed Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313–318CrossRefPubMed
12.
go back to reference Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157CrossRefPubMed Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157CrossRefPubMed
13.
go back to reference Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung YY, Weil E (2009) Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. doi:10.1097/RLI.0b013e31819343ba Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung YY, Weil E (2009) Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. doi:10.​1097/​RLI.​0b013e31819343ba​
14.
go back to reference Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C et al (2009) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. doi:10.1016/j.ejrad.2008.11.021 Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C et al (2009) Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. doi:10.​1016/​j.​ejrad.​2008.​11.​021
15.
go back to reference Perazella MA (2009) Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 4:461–469CrossRefPubMed Perazella MA (2009) Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 4:461–469CrossRefPubMed
16.
go back to reference Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA (2009) Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment–report of 33 cases. Radiology 250:371–377CrossRefPubMed Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA (2009) Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment–report of 33 cases. Radiology 250:371–377CrossRefPubMed
17.
go back to reference Thomsen HS, Marckmann P (2008) Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 66:180–183CrossRefPubMed Thomsen HS, Marckmann P (2008) Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 66:180–183CrossRefPubMed
18.
go back to reference Thomsen HS (2007) ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17:2692–2696CrossRefPubMed Thomsen HS (2007) ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17:2692–2696CrossRefPubMed
19.
go back to reference Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST et al (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175CrossRefPubMed Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST et al (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175CrossRefPubMed
20.
go back to reference Thakral C, Alhariri J, Abraham JL (2007) Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2:199–205CrossRefPubMed Thakral C, Alhariri J, Abraham JL (2007) Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2:199–205CrossRefPubMed
21.
go back to reference Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–280PubMedCrossRef Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273–280PubMedCrossRef
22.
go back to reference Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66:230–234CrossRefPubMed Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66:230–234CrossRefPubMed
Metadata
Title
Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents
Authors
Hanno Hoppe
Sara Spagnuolo
Johannes M. Froehlich
Helga Nievergelt
Hans-Peter Dinkel
Silvia Gretener
Harriet C. Thoeny
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
European Radiology / Issue 3/2010
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-009-1586-0

Other articles of this Issue 3/2010

European Radiology 3/2010 Go to the issue